Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: DRM006
MIFTS: 68

Dermatitis

Categories: Skin diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Dermatitis

About this section

MalaCards integrated aliases for Dermatitis:

Name: Dermatitis 12 55 44 15 73
Eczema 12 76 29 55 6 43 63 73
Skin Inflammation 12 15
Inflammatory Dermatosis 73

Classifications:

MalaCards categories:
Anatomical: Skin diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:2723
MeSH 44 D003872
NCIt 50 C2983
SNOMED-CT 68 43116000 4979002
Sources

Summaries for Dermatitis

About this section
MedlinePlus : 43 Eczema is a term for several different types of skin swelling. Eczema is also called dermatitis. Most types cause dry, itchy skin and rashes on the face, inside the elbows and behind the knees, and on the hands and feet. Scratching the skin can cause it to turn red, and to swell and itch even more. Eczema is not contagious. The cause is not known. It is likely caused by both genetic and environmental factors. Eczema may get better or worse over time, but it is often a long-lasting disease. People who have it may also develop hay fever and asthma. The most common type of eczema is atopic dermatitis. It is most common in babies and children but adults can have it too. As children who have atopic dermatitis grow older, this problem may get better or go away. But sometimes the skin may stay dry and get irritated easily. Treatments may include medicines, skin creams, light therapy, and good skin care. You can prevent some types of eczema by avoiding Things that irritate your skin, such as certain soaps, fabrics, and lotions Stress Things you are allergic to, such as food, pollen, and animals NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Dermatitis, also known as eczema, is related to allergic contact dermatitis and contact dermatitis, and has symptoms including pruritus and exanthema. An important gene associated with Dermatitis is FLG (Filaggrin), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Zinc and Zinc oxide have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A skin disease characterized by itchy, erythematous, vesicular, weeping and crusting patches of skin.

PubMed Health : 63 About eczema: Eczema is a common, chronic, non-infectious skin condition. The main symptom of this inflammatory disease is a very itchy rash. It often affects children. In many cases eczema gets better as the years go by, and it may go away for a while or disappear altogether. Acute flare-ups can really affect quality of life. The itching can be especially bad, making it difficult to concentrate and sleep well. Some people are embarrassed if their rash is visible to others. By taking good care of your skin, using medication and avoiding irritants and other things that can trigger the eczema, it is usually possible to relieve the symptoms at least enough to live a fairly normal life.Eczema is sometimes also called "atopic eczema" or "atopic dermatitis."

Wikipedia : 76 Dermatitis, also known as eczema, is a group of diseases that results in inflammation of the skin. These... more...

Sources

Related Diseases for Dermatitis

About this section

Diseases related to Dermatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 929)
# Related Disease Score Top Affiliating Genes
1 allergic contact dermatitis 34.3 FLG IFNG IL31 IL4 IL5
2 contact dermatitis 34.2 CCL22 FLG IFNG IL31 IL4 IL5
3 dermatitis, atopic 34.0 CCL11 CCL22 FLG IFNG IL13 IL31
4 nickel allergic contact dermatitis 34.0 IFNG IL13 IL4 IL5
5 eczema herpeticum 33.4 FLG IFNG TSLP
6 netherton syndrome 32.5 DSG1 FLG SPINK5
7 bullous pemphigoid 32.5 CCL11 DSG1 IL5
8 egg allergy 32.2 IL4 IL5
9 allergic rhinitis 32.2 CCL11 IFNG IL13 IL4 IL5
10 onchocerciasis 32.1 CCL11 IL13 IL4 IL5
11 asthma 31.9 CCL11 CCL22 FLG IFNG IL13 IL31
12 psoriasis 31.3 CCL22 FLG IFNG IL13 IL4
13 food allergy 31.1 FLG IFNG IL13 IL4 IL5
14 rhinitis 30.8 CCL11 IL13 IL4 IL5
15 lichen planus 30.7 FLG IFNG IL4
16 folliculitis 30.5 CCL11 IFNG IL4 IL5
17 conjunctivitis 30.5 CCL11 IFNG IL13 IL4 IL5
18 ige responsiveness, atopic 30.5 IFNG IL13 IL4 IL5 SPINK5
19 lichen disease 30.4 DSG1 FLG IFNG IL4
20 skin disease 30.4 CCL11 DSG1 FLG IFNG IL13 IL31
21 peanut allergy 30.3 CCL22 FLG IFNG IL13
22 keratoconjunctivitis 30.3 CCL11 IFNG IL13 IL4 IL5
23 sezary's disease 30.3 IFNG IL4 IL5
24 lymphadenitis 30.2 CCL22 IFNG NOD2
25 autoimmune disease 30.2 DSG1 IFNG IL4 IL5
26 lichen amyloidosis 30.2 IL31 IL31RA
27 hypereosinophilic syndrome 30.2 CCL11 IL13 IL4 IL5
28 allergic asthma 30.1 CCL11 IFNG IL13 IL4 IL5 TSLP
29 latex allergy 30.1 FLG IL13 IL4 IL5
30 cutaneous leishmaniasis 30.1 IFNG IL13 IL4 IL5
31 leishmaniasis 30.1 IFNG IL13 IL4 IL5
32 allergic conjunctivitis 30.0 CCL11 IFNG IL13 IL4 IL5
33 atopic keratoconjunctivitis 30.0 CCL22 IFNG IL4 IL5
34 allergic hypersensitivity disease 30.0 CCL11 CCL22 IFNG IL13 IL4 IL5
35 epidermolysis bullosa pruriginosa 30.0 FLG IL31
36 blepharoconjunctivitis 29.9 CCL11 IL4
37 pneumonia 29.9 CCL11 IL13 IL5
38 tetanus 29.9 IFNG IL13 IL4 IL5
39 schistosomiasis 29.9 IFNG IL13 IL4 IL5
40 respiratory allergy 29.9 CCL11 IL13 IL4 IL5 TSLP
41 eosinophilic gastroenteritis 29.9 CCL11 IL5 TSLP
42 gastroenteritis 29.8 CCL11 IL4 IL5 TSLP
43 inflammatory bowel disease 29.7 CCL11 IFNG IL13 IL4 IL5 NOD2
44 esophagitis 29.7 CCL11 DSG1 IL13 IL5 TSLP
45 aspergillosis 29.7 IFNG IL4 IL5
46 strongyloidiasis 29.7 CCL11 IFNG IL13 IL5
47 vernal keratoconjunctivitis 29.6 CCL11 IL13 IL4 IL5
48 uveitis 29.6 IFNG IL4 NOD2
49 bronchiolitis 29.6 CCL11 IFNG IL13 IL4 IL5
50 ascaris lumbricoides infection 29.6 IFNG IL13 IL5 TSLP

Graphical network of the top 20 diseases related to Dermatitis:



Diseases related to Dermatitis
Sources

Symptoms & Phenotypes for Dermatitis

About this section

UMLS symptoms related to Dermatitis:


pruritus, exanthema

GenomeRNAi Phenotypes related to Dermatitis according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.55 MSMO1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.55 IL13
3 Increased shRNA abundance (Z-score > 2) GR00366-A-128 9.55 IL13
4 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.55 IL13
5 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.55 MSMO1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.55 MSMO1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-186 9.55 NACA
8 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.55 FAF2 IL13 MSMO1 NACA
9 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.55 MSMO1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.55 NACA
11 Increased shRNA abundance (Z-score > 2) GR00366-A-39 9.55 IL13
12 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.55 FAF2 MSMO1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-6 9.55 NACA

MGI Mouse Phenotypes related to Dermatitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.03 BTD CARD11 FAF2 IFNG IL13 IL31RA
2 hematopoietic system MP:0005397 10.02 CARD11 CCL11 IFNG IL13 IL31RA IL4
3 immune system MP:0005387 9.9 CARD11 CCL11 CCL22 IFNG IL13 IL31RA
4 integument MP:0010771 9.56 BTD CARD11 DSG1 IFNG IL13 IL4
5 respiratory system MP:0005388 9.17 CARD11 CCL11 IFNG IL13 IL4 IL5
Sources

Drugs & Therapeutics for Dermatitis

About this section

PubMedHealth treatment related to Dermatitis: 63

Eczema is a chronic condition. Treatment cannot cure it, but regular skin care and medication can help to keep the itching and rash at bay. The main treatment options are:Basic treatment: Lipid-replenishing and moisturizing products (emollients) are generously applied to the skin at least twice a day to keep it from drying out. This can help relieve itching and protect the skin from germs and irritants.Special soaps, liquid cleansers and shampoos: Normal soaps and products like shampoo or shower gel contain various substances that can dry out your skin. Special cleansing products without these substances are available to get around this problem. But basic treatment with emollients can usually compensate for the loss of moisture caused by normal soaps.Steroid creams: Eczema flare-ups are usually treated with steroid creams because they can relieve the itching and inflammation. They are typically used only for acute symptoms. But they are sometimes used at regular intervals together with moisturizing skin care products (basic treatment): for example, as a "weekend treatment" where a steroid cream is applied on one or two days a week.Pimecrolimus and tacrolimus: Pimecrolimus and tacrolimus are two other medicines that can be used to treat eczema. They are not approved for use in children under the age of two years, though. These two medicines are also applied to the skin in a cream or ointment, and can be used if steroid products are not an option. This might be the case if steroid treatment is not tolerated or is ineffective. Pimecrolimus and tacrolimus may also be an option for long-term treatment of sensitive skin in the face and neck area. They can also be used on one or two days per week only, as described above.Other eczema treatment options include wet wraps, UV radiation and medications that suppress certain immune responses. Tablets containing these medicines are used if other treatments don't work, or if the eczema is very severe or affects large areas of skin. Because they have an effect throughout the entire body, they may have more extensive side effects than topical treatments.Allergy medications (antihistamines) are also commonly used to relieve itching. But research has now shown that they are not suitable for treating eczema, whether used as tablets or a cream.People often try out herbal products or dietary supplements, such as evening primrose oil, borage oil, vitamin B6, vitamin E and zinc. But research hasn't shown that these products are effective.Many other treatments such as laser therapies or hyposensitization have not yet been studied enough, so they are not recommended by medical associations.

Drugs for Dermatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 615)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 7440-66-6
2
Zinc oxide Approved Phase 4,Phase 3,Phase 2,Not Applicable 1314-13-2
3
Montelukast Approved Phase 4,Not Applicable 158966-92-8 5281040
4
Petrolatum Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 8009-03-8
5
Titanium dioxide Approved Phase 4,Not Applicable 13463-67-7
6
Ethanol Approved Phase 4,Phase 3,Phase 1,Not Applicable 64-17-5 702
7
mometasone furoate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83919-23-7
8
Bacitracin Approved, Vet_approved Phase 4,Phase 3,Phase 2 1405-87-4 10909430 439542
9
Bronopol Approved Phase 4,Phase 3,Phase 2 52-51-7
10 Parthenolide Approved, Investigational Phase 4,Phase 3,Phase 2 20554-84-1
11
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-03-3
12
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-23-7 5754
13
Salicylic acid Approved, Investigational, Vet_approved Phase 4,Not Applicable 69-72-7 338
14
Isotretinoin Approved Phase 4,Phase 3,Not Applicable 4759-48-2 5538 5282379
15
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
16
Ciclopirox Approved, Investigational Phase 4,Phase 3 29342-05-0 2749
17
Glycerol Approved, Investigational Phase 4,Phase 3,Not Applicable 56-81-5 753
18
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 445643 439492
19
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 124-94-7 31307
20
Mineral oil Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 8042-47-5
21
Clobetasol Approved, Experimental, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 25122-46-7, 25122-41-2 5311051 32798
22
Cetuximab Approved Phase 4,Phase 3,Phase 2,Phase 1 205923-56-4 56842117 2333
23
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596
24
Chlorhexidine Approved, Vet_approved Phase 4,Not Applicable 55-56-1 2713 9552079
25
Desonide Approved, Investigational Phase 4,Phase 3,Not Applicable 638-94-8 5311066
26
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-45-6, 75614-87-8 774
27
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
28
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
29
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
30
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
31
Povidone Approved Phase 4,Phase 3,Phase 2,Not Applicable 9003-39-8
32
Loratadine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 79794-75-5 3957
33
Betamethasone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 378-44-9 9782
34
Desoximetasone Approved Phase 4 382-67-2 5311067
35
Fluocinonide Approved, Investigational Phase 4,Phase 2 356-12-7 9642
36
Pimecrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 137071-32-0 6447131 17753757
37
Fluticasone Approved, Experimental Phase 4,Phase 3,Early Phase 1 90566-53-3 62924
38
Cortisone acetate Approved, Investigational Phase 4,Phase 2 1950-04-4, 50-04-4 5745
39
Levocetirizine Approved Phase 4,Phase 3,Phase 1 130018-77-8 1549000
40
Cetirizine Approved Phase 4,Phase 3,Phase 2,Phase 1 83881-51-0 2678
41
Omalizumab Approved, Investigational Phase 4,Phase 2,Phase 1 242138-07-4
42
Ketoconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 65277-42-1 3823 47576
43
Methylprednisolone aceponate Approved, Vet_approved Phase 4,Phase 2,Phase 1 86401-95-8
44
Racepinephrine Approved Phase 4,Phase 2,Not Applicable 329-65-7 838
45
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 51-43-4 5816
46
Clindamycin Approved, Vet_approved Phase 4,Phase 2 18323-44-9 29029
47
Benzoyl peroxide Approved Phase 4 94-36-0 7187
48
Adapalene Approved Phase 4,Phase 1 106685-40-9 60164
49
Chitosan Approved Phase 4,Phase 2,Not Applicable 9012-76-4 71853
50
Glucosamine Approved, Investigational Phase 4 3416-24-8 439213

Interventional clinical trials:

(show top 50) (show all 1377)
# Name Status NCT ID Phase Drugs
1 Trial Comparing Calmoseptine Ointment and Desitin Diaper Rash Paste in Diaper Dermatitis in Neonates and Infants Unknown status NCT02716415 Phase 4 Calmoseptine Ointment;Destin Maximum Strength 40% Zinc
2 Effectiveness of a Combined Dermatological Treatment in Children With Atopic Dermatitis Unknown status NCT02920411 Phase 4
3 Does Treatment With Montelukast Improve Symptoms of Atopic Dermatitis in Children? Unknown status NCT02534467 Phase 4 Montelukast
4 Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients Unknown status NCT02495064 Phase 4 Mometasone Furoate Cream
5 Efficacy of KAM2904 Face Cream and KAM3008 Body Lotion Treatment in Children With Atopic Dermatitis (AD) Unknown status NCT01781663 Phase 4
6 Clinical Evaluation of T.R.U.E. Test Allergens in Children an Adolescents Unknown status NCT01797562 Phase 4 T.R.U.E. Test Panel 3.2
7 Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea Unknown status NCT01139749 Phase 4 oral isotretinoin;salicylic acid and ciclopirox olamine
8 Efficacy of Glycerol, Two Topical Steroids, and a Topical Immune Modulator Against Skin Irritation Unknown status NCT00779792 Phase 4 clobetasol;triamcinolone acetonide;tacrolimus;glycerol;vehicle ointment (paraffin oil/soft white paraffin)
9 Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE) Unknown status NCT01553032 Phase 4 Erbitux®
10 Quaternium-15, Use Test Unknown status NCT00311454 Phase 4 T.R.U.E.Test
11 The Randomized Controlled Clinical Trial of Kushen Injection Unknown status NCT02346318 Phase 4 Compound Kushen Injection
12 Effect of Moisturizing Creams on Skin Barrier Function Unknown status NCT00771121 Phase 4 urea/lactic acid;Placebo
13 Efficacy and Safety of Runzao Zhiyang Capsule to Treat Chronic Eczema Unknown status NCT02601222 Phase 4 Runzao zhiyang capsule;Runzaozhiyang capsule agent simulation;Urea cream
14 Chlorhexidine Gluconate Versus Mupirocin Ointment in the Prevention of Peritoneal Dialysis-Related Infection Unknown status NCT02547103 Phase 4
15 Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis Completed NCT02732314 Phase 4 Investigational OTC Cream;0.05% Desonide Cream
16 Evaluating Treatment Resistant Dermatitis TaroIIR Completed NCT03050294 Phase 4 Desoximetasone 0.25% spray
17 A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis Completed NCT01049243 Phase 4 Fluocinonide Cream 0.1%
18 Effects of Pimecrolimus Cream 1% on the Molecular and Cellular Profile of Adult Male Patients With Atopic Dermatitis Completed NCT00117377 Phase 4 Pimecrolimus;Placebo
19 An Efficacy and Safety Study of Tacrolimus Ointment in Adult Participants With Atopic Dermatitis Completed NCT01828879 Phase 4 Tacrolimus
20 An Efficacy and Safety Study of Tacrolimus Ointment in Pediatric Participants With Atopic Dermatitis Completed NCT01782729 Phase 4 Tacrolimus
21 Open Label Study of Long Term Treatment of Pediatric Treatment of Atopic Dermatitis With Pimecrolimus Cream 1% Within a Usual Clinical Setting Completed NCT00509990 Phase 4 Pimecrolimus
22 Topical Steroid Formulation and Wet Wraps Completed NCT02680301 Phase 4 0.1% triamcinolone CREAM;0.1% triamcinolone OINTMENT
23 Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Severe Atopic Dermatitis Completed NCT00832585 Phase 4 Alefacept
24 Comparison of Pimecrolimus Cream 1% Twice-Daily to Once-Daily Dosing in the Management of Atopic Dermatitis in Pediatric Subjects Completed NCT00139581 Phase 4 Pimecrolimus;Pimecrolimus
25 Proactive Treatment of Tacrolimus Ointment for Adult Facial Seborrheic Dermatitis Completed NCT01591070 Phase 4 Tacrolimus;Tacrolimus
26 Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis Completed NCT00693693 Phase 4 hydrocortisone 17-butyrate 0.1% Cream preparation;hydrocortisone 17-butyrate 0.1% Ointment preparation;hydrocortisone 17-butyrate 0.1% Lipocream preparation
27 Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis. Completed NCT01323673 Phase 4 clobetasol propionate 0.05%;Vehicle / Placebo
28 Analysis of the Quality of Life, the Clinical Effectiveness and Cost-effectiveness of a Novel Educational Programme in Patients With Psoriasis and Atopic Dermatitis Completed NCT01077882 Phase 4
29 Efficacy Study of Montelukast in Atopic Dermatitis Induced by Food Allergens Completed NCT00557284 Phase 4 Montelukast;Placebo
30 A Comparison Study Between Protopic (Tacrolimus) Ointment and Elidel (Pimecrolimus) Cream in Treating Subjects With Atopic Dermatitis Completed NCT00666302 Phase 4 tacrolimus ointment;pimecrolimus cream
31 Epiceramâ„¢ Device Versus Mid-Strength Topical Steroid (Fluticasone Propionate 0.05%) for Treatment of Atopic Dermatitis Completed NCT00616538 Phase 4 Fluticasone Propionate 0.05%
32 Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Treating Pediatric Patients With Atopic Dermatitis Completed NCT00666159 Phase 4 tacrolimus ointment;pimecrolimus cream
33 Pimecrolimus Cream 1% (Elidel®) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of Atopic Dermatitis. Completed NCT01177566 Phase 4 pimecrolimus
34 A Clinical Study in Children and Adolescents With Mild to Moderate Atopic Dermatitis Completed NCT00568412 Phase 4 Elidel
35 Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Pediatric Patients With Mild Atopic Dermatitis Completed NCT00667160 Phase 4 tacrolimus ointment;pimecrolimus cream
36 Measuring Adherence to Topical Therapy in Children With Atopic Dermatitis and the Impact of a Return Visit Completed NCT00654355 Phase 4 tacrolimus ointment
37 Study of the Safety and Efficacy of Tacrolimus Ointment in Treating Chronic Allergic Contact Dermatitis Completed NCT00667056 Phase 4 tacrolimus ointment;placebo ointment
38 Elidel-Study: Elidel in Patients With Atopic Dermatitis Completed NCT00180141 Phase 4 Elidel-Creme
39 Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis Completed NCT00690833 Phase 4 topical desonide hydrogel 0.05%
40 Evaluation of Cetaphil Advanced Usage to Control Light to Moderate Atopic Dermatitis, in Attempt to Reduce the Necessity of Topic Corticoids Application Completed NCT01063218 Phase 4
41 Combination Therapy for Atopic Dermatitis Completed NCT00119158 Phase 4 Combination of pimecrolimus and fluticasone;pimecrolimus
42 Management of Pruritus With Xyzal in Atopic Dermatitis Completed NCT00884325 Phase 4 Levocetirizine dihydrochloride (Xyzal);placebo
43 Epiceram Versus Elidel for Treatment of Mild to Moderate Atopic Dermatitis Completed NCT00460083 Phase 4 Elidel(R) (pimecrolimus 1%)
44 Trial on Effectiveness Combined Probiotics in Atopic Dermatitis in Children Completed NCT02519556 Phase 4 Probiatop;Placebo
45 Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis Completed NCT00121381 Phase 4 Pimecrolimus plus topical corticosteroid (TCS);Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)
46 Cetaphil Restoraderm Effect on Young Children With Atopic Dermatitis Completed NCT02589392 Phase 4
47 Locobase® REPAIR Used as an Adjunctive to Standard Therapy in Children With Moderate to Severe Atopic Dermatitis Completed NCT00673725 Phase 4 Locobase® REPAIR
48 Preventive Treatment of Tacrolimus Ointment in Children With Atopic Dermatitis Completed NCT01745159 Phase 4 tacrolimus
49 A Study to Investigate the Use of Hydrogel Vehicle in Maintaining the Skin Barrier in Persons With Atopic Dermatitis Completed NCT01065714 Phase 4 Hydrogel vehicle;Eucerin Lotion
50 Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis Completed NCT00130364 Phase 4 Pimecrolimus;Placebo

Search NIH Clinical Center for Dermatitis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: dermatitis

Sources

Genetic Tests for Dermatitis

About this section

Genetic tests related to Dermatitis:

# Genetic test Affiliating Genes
1 Eczema 29
Sources

Anatomical Context for Dermatitis

About this section

MalaCards organs/tissues related to Dermatitis:

41
Skin, Testes, T Cells, Colon, Neutrophil, Breast, Bone
Sources

Publications for Dermatitis

About this section

Articles related to Dermatitis:

(show top 50) (show all 10245)
# Title Authors Year
1
Occupational allergic contact dermatitis caused by colophonium. ( 30229960 )
2019
2
Allergic contact dermatitis caused by isopropyl lauroyl sarcosinate. ( 30238468 )
2019
3
Occupational allergic contact dermatitis caused by cobalt in machine oil. ( 30246382 )
2019
4
"Crossed" allergic contact dermatitis caused by oxidized vitamin K1 in a patient previously sensitized to non-oxidized vitamin K1. ( 30264888 )
2019
5
Allergic contact dermatitis caused by vinylpyrrolidone/eicosene copolymer in a sunscreen. ( 30304757 )
2019
6
Allergic contact dermatitis caused by Dermabond in a paediatric patient undergoing skin surgery. ( 30304758 )
2019
7
Allergic contact dermatitis caused by clindamycin. ( 30311633 )
2019
8
Occupational airborne allergic contact dermatitis caused by N-(4-hydroxyphenyl)benzenesulfonamide. ( 30334269 )
2019
9
Tertiary prevention of occupational skin diseases: Prevalence of allergic contact dermatitis and pattern of patch test results. ( 30506828 )
2019
10
Toll-Like Receptor 7 Agonist-Induced Dermatitis Causes Severe Dextran Sulfate Sodium Colitis by Altering the Gut Microbiome and Immune Cells. ( 30510995 )
2019
11
Severe contact dermatitis caused by urushiol in Japanese lacquer. ( 30175848 )
2019
12
What's the "buzz" about propolis? Propolis-induced systemic contact dermatitis. ( 30311211 )
2019
13
Contact Dermatitis: Emerging Trends. ( 30466685 )
2019
14
Topically applied low-dose calcitriol ameliorates atopic eyelid dermatitis. ( 30533473 )
2019
15
A CCR4 antagonist ameliorates atopic dermatitis-like skin lesions induced by dibutyl phthalate and a hydrogel patch containing ovalbumin. ( 30551395 )
2019
16
Rutaecarpine inhibited imiquimod-induced psoriasis-like dermatitis via inhibiting the NF-κB and TLR7 pathways in mice. ( 30551443 )
2019
17
A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis. ( 30554600 )
2019
18
"Tar smarts" may have a new meaning for atopic dermatitis and psoriasis. ( 30395913 )
2019
19
Atopic Dermatitis: New Developments. ( 30466683 )
2019
20
Mechanisms by Which Atopic Dermatitis Predisposes to Food Allergy and the Atopic March. ( 30479073 )
2019
21
Recall dermatitis at patch test sites in an atopic dermatitis patient treated with dupilumab. ( 30334260 )
2019
22
Sterile Pyogranulomatous Dermatitis and Panniculitis. ( 30390792 )
2019
23
Canine Acute Eosinophilic Dermatitis with Edema (Wells-Like Syndrome). ( 30390793 )
2019
24
Therapies in Canine Atopic Dermatitis: An Update. ( 30262146 )
2019
25
Diagnosis and Treatment of Canine Acral Lick Dermatitis. ( 30268424 )
2019
26
Chronic hand eczema in Germany: 5-year follow-up data from the CARPE registry. ( 30246346 )
2019
27
Alopecia areata after dupilumab for atopic dermatitis. ( 29387767 )
2018
28
The Genetics of Chronic Itch: Gene Expression in the Skin of Patients with Atopic Dermatitis and Psoriasis with SevereA Itch. ( 29317264 )
2018
29
Pathogenicity of blood orf virus isolates in the development of dairy goat contagious pustular dermatitis. ( 29778194 )
2018
30
Malassezia species retrieved from skin with pityriasis versicolor, seborrhoeic dermatitis and skin free of lesions: a comparison of two sampling methods. ( 29505089 )
2018
31
Allergic contact dermatitis caused by octylisothiazolinone in a leather sofa. ( 29790173 )
2018
32
Textile contact dermatitis caused by octylisothiazolinone in compression stockings. ( 29399813 )
2018
33
Could conjunctivitis in dupilumab treated atopic dermatitis patients be caused by colonization with Demodex and increased IL-17 levels? Reply from authors. ( 29336016 )
2018
34
Chemokine Signaling in Allergic Contact Dermatitis: Toward Targeted Therapies. ( 29939854 )
2018
35
Allergic contact dermatitis caused by acrylic-based medical dressings and adhesives. ( 29888412 )
2018
36
Increased interleukin-36I^ expression in skin and sera of patients with atopic dermatitis and mycosis fungoides/SAczary syndrome. ( 29314201 )
2018
37
A 8-year population-based cohort study of irritable bowel syndrome in childhood with history of atopic dermatitis. ( 29374025 )
2018
38
Declining prevalence of allergic contact dermatitis caused by tosylamide formaldehyde resin in nail polish. ( 29726606 )
2018
39
Validation of patient-reported global severity of atopic dermatitis in adults. ( 28905999 )
2018
40
Prenatal exposure to perfluoroalkyl and polyfluoroalkyl substances and childhood atopic dermatitis: a prospective birth cohort study. ( 29343261 )
2018
41
Expression of Elafin in Dermatitis Herpetiformis. ( 29293478 )
2018
42
Why now? Delayed drug-induced pancreatitis due to dapsone for dermatitis herpetiformis. ( 29915658 )
2018
43
Identification and interaction analysis of key genes and microRNAs in atopic dermatitis by bioinformatics analysis. ( 29974487 )
2018
44
Chronic Nasolabial Fold Seborrheic Dermatitis Successfully Controlled With Crisaborole. ( 29742192 )
2018
45
Treatment of hypereosinophilic syndrome and eosinophilic dermatitis with reslizumab. ( 29496465 )
2018
46
Potential inhibitory effects of the traditional herbal prescription Hyangso-san against skin inflammation via inhibition of chemokine production and inactivation of STAT1 in HaCaT keratinocytes. ( 29207093 )
2018
47
Exploring Immune Development in Infants With Moderate to Severe Atopic Dermatitis. ( 29966024 )
2018
48
Bilateral Periorbital Impetigo Inducing Significant Dermatitis and Cicatricial Eyelid Changes in an Adult. ( 29784090 )
2018
49
Treatment of seborrheic dermatitis: a comprehensive review. ( 29737895 )
2018
50
Novel association of a papuloerythroderma of Ofuji phenotype with dermatitis herpetiformis. ( 29664108 )
2018
Sources

Variations for Dermatitis

About this section
Sources

Expression for Dermatitis

About this section
Search GEO for disease gene expression data for Dermatitis.
Sources

Pathways for Dermatitis

About this section

Pathways related to Dermatitis according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.94 CARD11 CCL11 CCL22 DSG1 FAF2 IFNG
2
PEDF Induced Signaling 64
Show member pathways
 13.59 CCL11 CCL22 IFNG IL13 IL31 IL31RA
3
Cytokine Signaling in Immune system 66
Show member pathways
 13.2 CCL11 CCL22 IFNG IL13 IL31 IL31RA
4
Allograft rejection 1 37
Show member pathways
 12.79 CARD11 CCL11 IFNG IL13 IL4 IL5
5
Th17 cell differentiation 37
Show member pathways
 12.49 IFNG IL13 IL4 IL5 NOD2
6
T cell receptor signaling pathway 37
Show member pathways
 12.32 CARD11 IFNG IL4 IL5
7
JAK-STAT signaling pathway (KEGG) 37
Show member pathways
 12.31 IFNG IL13 IL4 IL5 TSLP
8
IL-17 Family Signaling Pathways 65
Show member pathways
 12.24 CCL11 IFNG IL13 IL4 IL5
9
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.14 IFNG IL13 IL4 IL5
10
Immune response IFN gamma signaling pathway 22
Show member pathways
 11.95 CCL11 CCL22 IFNG IL13 IL4 IL5
11
Microglia Activation During Neuroinflammation: Overview 65
Show member pathways
 11.9 IFNG IL13 IL4
12
Interleukin-4 and 13 signaling 66
11.88 CCL11 CCL22 IL13 IL4
13
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.86 IFNG IL4 IL5
14
Glucocorticoid receptor regulatory network 1
11.71 IFNG IL13 IL4 IL5
15
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.66 IFNG IL4 IL5
16
IL4-mediated signaling events 1
11.57 CCL11 IL4 IL5
17
Innate Lymphoid Cell Differentiation Pathways 65
11.56 IFNG IL13 IL4 IL5 TSLP
18
Lung fibrosis 1
11.5 CCL11 IL13 IL4 IL5
19
Interleukin-10 signaling 66
11.45 CCL22 IL13 IL4
20
Microglia Activation During Neuroinflammation: Microglia Polarization 65
11.4 CCL11 CCL22 IFNG IL13 IL4
21
Inflammatory Response Pathway 1
11.23 IFNG IL4 IL5
22
Cytokines and Inflammatory Response 1
11.13 IFNG IL13 IL4 IL5
23
G-protein signaling_RhoB regulation pathway 22
11.11 CCL11 CCL22 IL13 IL4 IL5
24
OX40 Pathway 64
11.04 IFNG IL13 IL4 IL5
25
G-protein signaling_Rap2B regulation pathway 22
10.92 CCL11 CCL22 IL13 IL4 IL5
26
Development and heterogeneity of the ILC family 1
10.86 IFNG IL13 IL4 IL5 TSLP
27
Th2 Differentiation Pathway 65
10.83 CCL11 CCL22 IFNG IL13 IL31 IL4
Sources

GO Terms for Dermatitis

About this section

Cellular components related to Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 BTD CCL11 CCL22 IFNG IL13 IL31
2 extracellular region GO:0005576 9.36 BTD CCL11 CCL22 FAF2 IFNG IL13

Biological processes related to Dermatitis according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.88 IFNG IL31RA IL5 NOD2 TSLP
2 immune response GO:0006955 9.8 CCL11 CCL22 IFNG IL13 IL4 IL5
3 cornification GO:0070268 9.69 DSG1 FLG SPINK5
4 response to virus GO:0009615 9.67 CCL11 CCL22 IFNG
5 positive regulation of B cell proliferation GO:0030890 9.56 CARD11 IL13 IL4 IL5
6 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.55 IFNG IL13 IL31RA IL4 TSLP
7 cytokine-mediated signaling pathway GO:0019221 9.5 CCL11 CCL22 IL13 IL31 IL31RA IL4
8 regulation of T cell differentiation GO:0045580 9.46 CARD11 SPINK5
9 positive regulation of interleukin-13 production GO:0032736 9.43 IL4 TSLP
10 negative regulation of complement-dependent cytotoxicity GO:1903660 9.4 IL13 IL4
11 T-helper 2 cell cytokine production GO:0035745 9.37 IL31RA IL4
12 regulation of signaling receptor activity GO:0010469 9.23 CCL11 CCL22 IFNG IL13 IL31 IL4

Molecular functions related to Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.23 CCL11 CCL22 IFNG IL13 IL31 IL4
2 CARD domain binding GO:0050700 9.16 CARD11 NOD2
3 cytokine receptor binding GO:0005126 9.13 IL13 IL31 IL4
Sources

Sources for Dermatitis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....